EP1411890A1 - Preparations cosmetiques et/ou pharmaceutiques contenant des extraits vegetaux - Google Patents

Preparations cosmetiques et/ou pharmaceutiques contenant des extraits vegetaux

Info

Publication number
EP1411890A1
EP1411890A1 EP02764769A EP02764769A EP1411890A1 EP 1411890 A1 EP1411890 A1 EP 1411890A1 EP 02764769 A EP02764769 A EP 02764769A EP 02764769 A EP02764769 A EP 02764769A EP 1411890 A1 EP1411890 A1 EP 1411890A1
Authority
EP
European Patent Office
Prior art keywords
plant
extracts
cajanus cajan
acid
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02764769A
Other languages
German (de)
English (en)
Inventor
Gilles Pauly
Philippe Moser
Louis Danoux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Health and Care Products France SAS
Original Assignee
Cognis France SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognis France SAS filed Critical Cognis France SAS
Priority to EP02764769A priority Critical patent/EP1411890A1/fr
Publication of EP1411890A1 publication Critical patent/EP1411890A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/12—Preparations containing hair conditioners

Definitions

  • the invention is in the field of cosmetics and relates to preparations containing special plant extracts and the use of these plant extracts in cosmetic and / or pharmaceutical preparations, for example for skin treatment.
  • the task of the skin as an organ enveloping the organism consists in sealing and mediating functions against the environment.
  • Different biochemical and biophysical systems serve to maintain the integrity of this exposed organ.
  • an immune system protects the skin from damage caused by pathogenic microorganisms
  • the melanin-forming system regulates pigmentation and protects the skin from radiation damage
  • a lipid system produces lipid micelles that contain the transdermal water loss
  • regulated keratin synthesis provides the mechanically resistant horny layer.
  • the systems mentioned are based on complex chemical processes, the course of which is kept going, inter alia, by enzymes and regulated by enzyme inhibitors. Even a slight inhibition or disinhibition of these biochemical systems manifests itself in noticeable changes in the skin.
  • the visible and tangible condition of the skin is, however, a yardstick for beauty, health and youth; Preserving it is a general goal of nourishing cosmetics.
  • the human skin usually reacts to exogenous, i.e. external stress factors, such as UV radiation, ozone or other harmful substances in the air (environmental pollution) with mild or severe irritation.
  • external stress factors such as UV radiation, ozone or other harmful substances in the air (environmental pollution)
  • the skin is damaged by the oxygen radicals and non-specific proteinases released in irritation reactions.
  • this can have a negative effect on the appearance or the elasticity or the barrier functions of the skin.
  • excess mobilized body proteases such as tryptases, elastases, collagenases and cathepsins, can attack the skin and, in particular, its structural proteins such as collagen and elastin.
  • Plant extracts have been used in many different cultures for medical as well as for cosmetic purposes for many years. New plants are extracted again and again and the extracts are examined for their cosmetic effects in order to add new plants or plants to find a modified spectrum of activity. Many plants, the benefits of which were not yet known, and which were considered to be exotic and insignificant, are widely used today, among other things, in cosmetics.
  • Cosmetic preparations are available to the consumer in a variety of combinations today. Not only is it expected that these cosmetics have a certain nourishing effect or remedy a certain deficiency, but more and more people are asking for products that have several properties at the same time and thus show an improved range of services.
  • substances that both positively influence the technical properties of the cosmetic product such as storage stability, light stability and formulability, and at the same time represent active substances that impart nourishing, anti-irritant, anti-inflammatory and / or light-protective properties for the skin and / or hair. Good skin tolerance and the use of natural products by the customer are particularly important.
  • the object of the present patent application was to provide cosmetic and / or pharmaceutical preparations which meet the requirements for cosmetic formulations such as storage stability and skin compatibility and, in addition to caring properties, above all have improved protective properties for human skin and / or hair, for example against Have UV radiation and other environmental influences and at the same time have preventive and curative effects in the event of signs of aging of the skin and can be used in an anti-inflammatory manner.
  • Another object of the present patent application was to provide preparations which contain active ingredients from renewable raw materials and, at the same time, can be used in many ways as care products in cosmetics, both in skin cosmetics and in hair care.
  • the invention relates to cosmetic and / or pharmaceutical preparations containing an extract of the plant Cajanus cajan. Cosmetic and / or dermopharmaceutical preparations are preferred.
  • plant means both whole plants and parts of plants (branches, leaves, flowers, fruiting bodies, pericarp, root) and mixtures thereof. Extraction of leaves is preferred.
  • preparation, agent and care agent are used synonymously in the sense of the invention.
  • the extracts to be used according to the invention are obtained from the Cajanus cajan plant.
  • This plant is also known as Synonyma Cajanus indicus, Cytisus cajan, Pigeon Pea, Pigeon Pea, Pea Bean and Pigeon pea.
  • This plant is 0.5 to 4 m high, widely branched shrubs or bushes, with a thin root system up to 2 m long, which are also referred to as tap roots.
  • the stems are up to 15 cm in diameter.
  • the leaves appear alternately as three-leaf, glandular, elliptical leaves with a size of 13-13.7 cm x 1.3 - 5.7 cm. It produces yellow or red-yellow flowers in upright, loose clusters.
  • the plant and especially the leaves are already used as a diuretic. It is used against a wide variety of skin diseases.
  • the leaves and unripe fruit are used as envelopes to improve milk secretion.
  • the extracts to be used according to the invention are produced by customary methods of extracting plants or parts of plants.
  • suitable conventional extraction methods such as maceration, remaceration, digestion, movement maceration, vortex extraction, ultrasound extraction, countercurrent extraction, percolation, repercolation, evacolation (extraction under reduced pressure), diacolation and solid-liquid extraction under continuous reflux , which is carried out in a Soxhlet extractor, which is familiar to a person skilled in the art and in principle all can be used, is exemplary of Hager's Handbook of Pharmaceutical Practice, (5th Edition, Vol. 2, pp. 1026-1030, Springer Verlag, Berlin- Heidelberg-New York 1991).
  • Fresh plants or parts of plants can be used as the starting material, but plants and / or parts of plants which can be mechanically comminuted before extraction are usually used. Extraction of the leaves is particularly preferred. All grinding methods known to the person skilled in the art are suitable here, for example crushing with a mortar.
  • Organic solvents water (distilled or non-distilled, preferably hot water at a temperature of above 80 ° C.) or mixtures of organic solvents and water, in particular low molecular weight alcohols, preferably methanol, ethanol and propanol, esters, are preferably used as solvents for carrying out the extractions.
  • Hydrocarbons, ketones or halogenated hydrocarbons with more or less high water contents can be used.
  • Extraction with water, methanol, ethanol, pentane, hexane, heptane, acetone, propylene glycols, polyethylene glycols, ethyl acetate, dichloromethane, trichloromethane and mixtures thereof is particularly preferred, and water, methanol, ethanol and mixtures thereof are particularly preferred.
  • the extraction is usually carried out at 20 to 100 ° C, preferably at 30 to 90 ° C, in particular at 50 to 90 ° C. In one possible embodiment, the extraction takes place under an inert gas atmosphere to avoid oxidation of the ingredients of the extract.
  • the extraction times are determined by the person skilled in the art depending on the starting material, the extraction process, the extraction temperature, the ratio of solvent to raw material, etc.
  • the crude extracts obtained can optionally be subjected to further customary steps, such as purification, concentration and / or decolorization. If desired, the extracts produced in this way can, for example, be subjected to a selective separation of individual undesirable ingredients.
  • the present invention includes the knowledge that the extraction conditions and the yields of the final extracts can be selected depending on the desired field of use.
  • the extracts are then particularly preferably subjected to spray or freeze drying.
  • the extract of the plant Cajanus cajan can, however, also be carried out by extraction with supercritical carbon dioxide alone or in combination with a co-solvent.
  • the end product obtained can be composed of at least one fraction of a crude extract isolated and purified by chromatography, adsorption / desorption or liquid / liquid extraction. In this way, different specifications and salary settings can be met.
  • Cosmetic and / or pharmaceutical preparations based on the Cajanus cajan plant show surprisingly good nourishing and protective properties for the skin and hair, against stress and against environmental influences as well as good skin tolerance.
  • the preparations obtained in this way are further distinguished by a high antioxidative capacity, which on the one hand protects the skin from inflammatory reactions and against oxidative skin aging processes, and on the other hand protects the cosmetic agents from oxidative degradation (spoilage).
  • the products obtained in this way are suitable for counteracting the damage to human fibroblasts and keratinocytes by UV radiation and can therefore be used as sunscreens in cosmetics. They show proteinase-inhibiting properties and counteract non-enzymatic glycosylation; both effects also protect against skin aging.
  • the extracts according to the invention contain an active substance content in the extracts of 5 to 100% by weight, preferably 10 to 95% by weight, in particular 20 to 80% by weight.
  • the active substance content in the sense of the invention denotes the sum of all active substances present in the extract, based on the dry weight of the extract.
  • Active substance in the sense of the invention relates to the ingredients contained in the extract even if their content and identity cannot yet be demonstrated using conventional methods known to the person skilled in the art. Active ingredients within the meaning of the invention are furthermore to be understood as meaning all ingredients obtained in the extract, the effect of which is either already known, or the effect of which has not yet been able to be demonstrated using conventional methods known to the person skilled in the art.
  • Active substance in the sense of the invention relates to the proportion of substances and auxiliaries and additives contained in the agent, with the exception of the additionally added water.
  • the amount of plant extracts used in the preparations mentioned depends on the concentration of the individual ingredients and on the manner in which the extracts are used. As a rule, 0.001 to 25 wt ° / 0i preferably 0.03 to 10 wt .-%, 0.01 to 8 wt .-%, preferably 0.1 to 5 wt .-%, and particularly preferably 1 to 3 %
  • 0.001 to 25 wt ° / 0i preferably 0.03 to 10 wt .-%, 0.01 to 8 wt .-%, preferably 0.1 to 5 wt .-%, and particularly preferably 1 to 3 %
  • the total proportion of auxiliaries and additives can be 1 to 50, preferably 5 to 40% by weight, based on the final preparation of the cosmetic and / or pharmaceutical preparations.
  • the preparations can be produced by customary cold or hot processes; the phase inversion temperature method is preferably used.
  • the extracts of the plant Cajanus cajan generally contain ingredients from the group consisting of flavonoids, tannins, phytosterols, proteins, carbohydrates, phenolic acids and triterpenes. These are composed differently depending on the selected starting material and the selected extraction method.
  • tannins are understood to mean those which can be isolated from the Cajanus cajan plant.
  • they are polyphenols, which are also known as gallotannins due to their descent from gallic acid. They represent mixtures of substances of the pentadigalloyl glucose type (C76H52046, MR 1701, 22).
  • they are substances which, by oxidative coupling of the galloyl residues in 1, 2,3,4,6-pentagalloyl-D-glucose arise, as well as their subsequent products.
  • phytosterols are to be understood as sterols which can be isolated from the Cajanus cajan plant. They have a double bond at C-22 and C1 or C2 substituents at C-24. Ergosterol, stigmasterol, sitosterol, in particular ⁇ -sitosterol, are particularly preferred.
  • proteins are to be understood as all proteins which can be isolated from the Cajanusn cajan plant. Their share in the dry weight of the extract is between 15 and 25%, in particular 15 to 20%. Proteins are part of the plant plasma and can therefore be found in all parts of the plant, but mainly in the fruit.
  • carbohydrates are understood to be those which can be isolated from the Cajanus cajan plant.
  • Cellulose, glucan, inulin, agar-agar, carrageenan and alginic acid are preferably to be understood by this.
  • lignin is also found in the plant extract.
  • phenolic acids are understood to mean those which can be isolated from the Cajanuns cajan plant. They occur in free form or as esters or glycosides. This should preferably be understood to mean p-hydroxybenzoic acid and o-hydroxybenzoic acid, protocatechuic acid, vanillic acid, caffeic acid, p-coumaric acid, ferulic acid or salicylic acid.
  • triterpenes are to be understood as triterpenes which can be isolated from the Cajanus cajan plant.
  • the triterpenes according to the invention can be formally understood as polymerization products of the hydrocarbon isoprene.
  • the triterpenes (C30) are formed from three isoprene residues. Different polycyclic ring systems for the possible triterpenes can be derived from different folding options of the three isoprene residues.
  • the cyclization preferably gives 6 rings, in addition to most tetra- (e.g. cucurbitacins) and some pentacyclic (e.g. Lupane) triterpenes 5-rings. Since the 6-rings are in the form of armchairs and tubs, the 5-rings can be flat or angled, many different scaffolds are possible.
  • the present invention includes the finding that particularly effective cosmetic agents are obtained by the interaction of the ingredients of the plant extracts, in particular the abovementioned.
  • sunscreens in particular in agents against damage to human skin cells by UV radiation, in particular fibroblasts and / or keratinocytes by UVA radiation and / or UVB radiation;
  • protease inhibiting agent in particular as an MMP, collagenase and / or elastase inhibiting agent.
  • Care products for the purposes of the invention are care products for skin and hair. These care products include, among other things, cleaning and building effects as well as UV light protection properties.
  • the extracts according to the invention can be used in all cosmetic products. Examples of cosmetic products are described in their formulations in Tables 10 to 13.
  • the aim of hair care is to maintain the natural state of freshly regrown hair for as long as possible or to restore it if it is damaged.
  • Characteristics of natural healthy hair are silky shine, low porosity, resilient yet soft fullness and a pleasantly smooth feeling (good "grip").
  • the care products according to the invention have a smoothing effect on the hair, they improve combability, reduce the electrostatic charge and improve the feel and shine.
  • the preparations according to the invention show an excellent skin-care effect with high skin tolerance at the same time. In addition, they show good stability, in particular against oxidative decomposition of the products.
  • Another object of the invention is the use of extracts of the plant Cajanus cajan in care products with a soothing, beneficial and anti-irritant effect, in particular for sensitive and / or damaged skin and / or scalp.
  • Sunscreen or UV light protection factors
  • Another object of the invention is the use of the extracts of the plant Cajanus cajan in
  • Sunscreens or UV light protection factors in the sense of the invention are light protection agents which are useful for protecting human skin against the damaging effects of direct and indirect radiation from the sun.
  • the one responsible for skin tanning is the one responsible for skin tanning
  • UV-C Wavelengths 200-280 nm
  • UV-B The pigmentation of normal skin under the influence of solar radiation, i.e. H. the formation of melanins is caused differently by UV-B and UV-A. Irradiation with UV-A rays ("long-wave UV”) results in the darkening of the melanin bodies already present in the epidermis, without any damaging influences being recognizable. This is different with the so-called “short-wave UV” (UV-B) , This causes the development of so-called late pigment through the formation of new melanin grains.
  • UV-B short-wave UV
  • the skin is exposed to unfiltered radiation, which - depending on the duration of exposure - leads to the formation of reddened skin (erythema), skin inflammation (sunburn) and the like. can even cause blisters.
  • Extracts of the Cajanus cajan plant are used as UV absorbers, which convert the UV radiation into harmless heat. These can also be present in combination with other sunscreens or UV light protection factors.
  • UV light protection factors are, for example, liquid or crystalline organic substances (light protection filters) at room temperature, which are able to absorb ultraviolet rays and absorb the energy in the form of longer-wave radiation, e.g. To give off heat again.
  • UVB filters can be oil-soluble or water-soluble. As oil-soluble substances e.g. to call:
  • 4-aminobenzoic acid derivatives preferably 2-ethylhexyl 4- (dimethylamino) benzoate, 2-octyl 4- (dimethylamino) benzoate and amyl 4- (dimethylamino) benzoate;
  • esters of cinnamic acid preferably 4-methoxycinnamic acid 2-ethylhexyl ester, 4-methoxycinnamic acid propyl ester, 4-methoxycinnamic acid isoamyl ester 2-cyano-3,3-phenylcinnamic acid 2-ethylhexyl ester (octocrylene);
  • esters of salicylic acid preferably salicylic acid 2-ethylhexyl ester, salicylic acid 4-isopropylbenzyl ester, salicylic acid homomethyl ester;
  • benzophenone preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone;
  • Esters of benzalmalonic acid preferably di-2-ethylhexyl 4-methoxybenzmalonate; > Triazine derivatives, such as 2,4,6-trianilino- (p-carbo-2'-ethyl-1'-hexyloxy) -1, 3,5-triazine and octyl triazone, as described in EP 0818450 A1 or Dioctyl butamido triazone (Uvasorb® HEB);
  • UVA filters '-methoxydibenzoyl-methane
  • 1-phenyl-3- (4'-isopropylphenyl) propane-1,3-dione and enamine compounds as described for example in DE 19712033 A1 (BASF).
  • the UV-A and UV-B filters can of course also be used in mixtures.
  • insoluble light protection pigments namely finely dispersed metal oxides or salts
  • suitable metal oxides are, in particular, zinc oxide and titanium dioxide and, in addition, oxides of iron, zirconium, silicon, manganese, aluminum and cerium and mixtures thereof.
  • Silicates (talc), barium sulfate or zinc stearate can be used as salts.
  • the oxides and salts are used in the form of the pigments for skin-care and skin-protecting emulsions.
  • the particles should have an average diameter of less than 100 nm, preferably between 5 and 50 nm and in particular between 15 and 30 nm.
  • the pigments can also be surface treated, i.e. are hydrophilized or hydrophobized.
  • Typical examples are coated titanium dioxides, e.g. Titanium dioxide T 805 (Degussa) or Eusolex® T2000 (Merck). Silicones, and in particular trialkoxyoctylsilanes or dimethicones, are particularly suitable as hydrophobic coating agents. So-called micro- or nanopigments are preferably used in sunscreens. Micronized zinc oxide is preferably used.
  • the extracts of the plant Cajanus cajan are used in agents against damage to human skin cells by UV radiation, in particular fibroblasts and / or keratinocytes by UVA radiation and / or UVB radiation and / or as anti-inflammatory additives used.
  • UVA rays penetrate into the dermis, where they lead to oxidation stress, which is demonstrated by lipoperoxidation of the cytoplasmic membranes.
  • the lipoperoxides become too Malonaldialdehyde (MDA) is broken down, which will crosslink many biological molecules such as proteins and nucleic bases (enzyme inhibition or mutagenesis).
  • MDA Malonaldialdehyde
  • the extracts of the plant Cajanus cajan according to the invention significantly reduce the level of MDA in human fibroblasts, which is induced by UVA rays, and thus show a high capacity to reduce the harmful effects of oxidative stress on the skin.
  • UVB rays trigger inflammation by activating an enzyme, namely phospholipase A2 or PLA2.
  • This inflammation is triggered by the removal of arachidonic acid from the phospholipids of the plasma membrane by the phospholipase.
  • the degree of release of the cytoplasmic enzyme LDH (lactate dehydrogenase) in human keratinocytes serves as a marker for cell damage.
  • the extracts of the plant Cajanus cajan according to the invention reduce the effect of UVB radiation on the number of keratinocytes and on the content of released LDH.
  • the extracts therefore show the ability to reduce the damage to cell membranes caused by UVB radiation.
  • the use of the extracts according to the invention as anti-inflammatory additives is in principle possible for all cosmetic and / or pharmaceutical preparations which are used for inflammation of the skin and thus in skin care.
  • the inflammation of the skin can have a variety of causes.
  • Antioxidants for the purposes of the invention are oxidation inhibitors which can be isolated from the Cajanus cajan plant. Antioxidants are able to inhibit or prevent the undesirable changes in the substances to be protected caused by the effects of oxygen and other oxidative processes. The effect of the antioxidants is mostly that they act as a radical scavenger for the free radicals that occur during autoxidation.
  • antioxidants In addition to the use of extracts from the Cajanus cajan plant as antioxidants, other known antioxidants can also be used.
  • further typical examples are amino acids (e.g. glycine, alanine, arginine, serine, threonine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (e.g. urocanic acid) and their derivatives, peptides such as D, L-carnosine, D.
  • thioredoxin glutathione, Cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters) and their salts, dilaurylthiodipropionate, distearylthiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (e.g.
  • buthioninsulfoximines homocysteine sulfoximine, Butioninsulfone, penta-, hexa-, himinathinsins very low dosages
  • e.g. pmol to ⁇ mol / kg also (metal) chelators (e.g. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), ⁇ -hydroxy acids (e.g.
  • citric acid citric acid, lactic acid, malic acid
  • humic acid bile acid, bile extracts, bilirubin, biliverdin, boldine , Boldo extract, EDTA, EGTA and their derivatives
  • unsaturated fatty acids and their derivatives eg ⁇ -linolenic acid, linoleic acid, oleic acid
  • folic acid and their derivatives ubiquinone and ubiquinol and their der derivatives
  • vitamin C and derivatives e.g. ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate
  • tocopherols and derivatives e.g.
  • vitamin E acetate
  • vitamin A and derivatives vitamin A palmitate
  • Z and its derivatives e.g. Z and its derivatives (e.g. Z and its derivatives, e.g. Methionine), stilbenes and their derivatives (for example stilbene oxide, trans-stilbene oxide) and the derivatives suitable according to the invention (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of these active substances.
  • stilbenes and their derivatives for example stilbene oxide, trans-stilbene oxide
  • the derivatives suitable according to the invention salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids
  • the further UV light protection factors or further antioxidants can be added in amounts of 0.01 to 25, preferably 0.03 to 10 and in particular 0.1 to 5% by weight, based on the total amount in the preparations.
  • Rosacea is a chronic skin lesion whose cause is still unknown. The manifestations on the skin are very different. In most cases it appears as persistent reddening of the skin, especially the facial skin. Rosacea causes bumps and rashes.
  • Another object of the invention is the use of extracts from Cajanus cajan as an agent against hormonal and / or bacterial skin changes, especially against acne.
  • these skin changes include in particular all types of acne.
  • the agents and extracts from Cajanus cajan according to the invention continue to act against skin aging and can be used for the preventive or curative treatment of signs of aging of the skin.
  • Another name for this type of care product is anti-aging.
  • These signs of aging include any type of wrinkles and wrinkles. Treatments include slowing skin aging.
  • the signs of aging can have a variety of causes. In particular, these signs of aging are caused by damage to the skin induced by UV radiation.
  • the extracts from Cajanus cajan act as protease inhibiting agents, in particular as MMP and / or collagenase and / or elastase inhibiting agents.
  • MMP is understood to be matrix metalloproteases.
  • the matrix metallo-proteases include collagenase, but also a certain type of elastase.
  • the activity of the enzymes depends on metal ions - often they are Zn 2+ ions.
  • the macrophages and polymorphonuclear neutrophilic granulocytes release proteases such as, for example, the serine protease elastase or matrix metalloproteases (MMP) such as collagenase and another elastase which degrades to the MMP.
  • proteases such as, for example, the serine protease elastase or matrix metalloproteases (MMP) such as collagenase and another elastase which degrades to the MMP.
  • MMP-1 matrix metalloproteases
  • proteases catalyze the fragmentation and destruction of the dermal macromolecules such as proteoglycan, collagen and elastin. They thus weaken the connective tissue and thus lead to aging of the skin and to the effects of natural skin aging after UV radiation.
  • the main elastase belongs to the group of serine proteases. Their catalytic reaction is based on a different mechanism. These proteases (collagenase and the different elastases) catalyze the fragmentation and destruction of the dermal macromolecules such as proteoglycan, collagen and elastin and thus lead to the aging of the skin and to the effects of natural skin aging after UV radiation
  • the agents and extracts from Cajanus cajan according to the invention have an anti-glycosylation activity, in particular they act against the glycosylation of cutaneous proteins and preferably against the glycosylation of collagen.
  • A. Cerami described the glycosylation of proteins or non-enzymatic glycosylation in contrast to the enzymatic glycosylation by glucosyltransferase and mentioned the possible role of this glycosylation in the aging of tissues.
  • the biochemical mechanism of this reaction is well known (Borel J.P. et al., CR biologie prospective, 145-149, 1993) and takes place in two phases:
  • reducing sugars glucose, fructose
  • Schiff bases these compounds are then stabilized by Amadori rearrangement to the ketoamine.
  • the ketoamine functions are then oxidized to deoxy- onose in the presence of oxygen in a late phase and react with other basic amino acids such as arginine or lysine belonging to other proteins (albumin, lipoproteins, immunoglobulin).
  • AGE Advanced Glycosylation End Products
  • advanced glycosylation products as complex and very stable end products.
  • glycosylation of the proteins leads to the formation of inter- and intramolecular bridges in slowly renewed proteins and finally to the brown color and insolubility of these proteins. Glycosylation particularly affects the proteins in the extracellular matrices, the renewal of which is slow.
  • the proteins damaged by the glycosylation are in particular fibronectin, laminin, elastin and the various types of collagen.
  • glycosylated molecules lose their flexibility (tissue stiffening),
  • glycosylated molecules can become more resistant to enzymes that ensure their renewal and thus form surfaces from amorphous substances.
  • glycosylated proteins are metabolically and cellularly eliminated, in particular by macrophage degradation, which induces a redesign of the dermis.
  • glycosylated proteins represent a potential source of free oxygen radicals. This phenomenon, which is enhanced by UV-A, leads to collagen breakdown,
  • cytokines TNF-alpha
  • agents that counteract glycosylation can be used directly against hair loss. If these agents additionally show UV / IR light protection as has been demonstrated for the agents according to the invention, they fulfill the desired diverse effect here.
  • compositions according to the invention containing extracts from Cajanus cajan improve the combability of the hair and in particular the combability of dry hair.
  • This activity allows the use in any hair care products such as hair shampoo, hair lotion, hair conditioner, hair conditioner, hair fixer and in particular the use in combined preparations that allow daily use on wet or dry hair as well as on bleached or permed hair.
  • Another object of the invention is a method for producing an extract of the plant Cajanus cajan, in which solvents or mixtures of these solvents are used for the extraction, which are selected from the group consisting of distilled or undistilled water, low molecular weight alcohols, esters Hydrocarbons, ketones or halogenated hydrocarbons and the extract thus obtained is optionally dried.
  • solvents or mixtures of these solvents are used for the extraction, which are selected from the group consisting of distilled or undistilled water, low molecular weight alcohols, esters Hydrocarbons, ketones or halogenated hydrocarbons and the extract thus obtained is optionally dried.
  • a method is preferred in which distilled water, methanol, ethanol or mixtures of water and methanol or water and ethanol are used for the extraction.
  • the extracts according to the invention can be used in cosmetic and / or pharmaceutical preparations, such as hair shampoos, hair lotions, foam baths, shower baths, creams, gels, lotions, sunscreens, alcoholic and aqueous / alcoholic solutions, emulsions, wax / fat masses, stick preparations, powders or ointments can be used.
  • cosmetic and / or pharmaceutical preparations such as hair shampoos, hair lotions, foam baths, shower baths, creams, gels, lotions, sunscreens, alcoholic and aqueous / alcoholic solutions, emulsions, wax / fat masses, stick preparations, powders or ointments can be used.
  • These preparations can also be used as further auxiliaries and additives, mild surfactants, oil bodies, emulsifiers, pearlescent waxes, consistency agents, thickeners, superfatting agents, stabilizers, polymers, silicone compounds, fats, waxes, lecithins, phospholipids, biogenic active substances, UV light protection factors, antioxidants, deodorants, Antiperspirants, antidandruff agents, film formers, swelling agents, insect repellents, self-tanners, tyrosinase inhibitors (depigmentation agents), hydrotropes, solubilizers, preservatives, perfume oils, dyes and the like.
  • mild surfactants oil bodies, emulsifiers, pearlescent waxes, consistency agents, thickeners, superfatting agents, stabilizers, polymers, silicone compounds, fats, waxes, lecithins, phospholipids, biogenic active substances, UV light protection factors, antioxidants, deodorants, Antiperspirants, antidand
  • Auxiliaries and additives with surface activity may contain anionic, nonionic, cationic and / or amphoteric or amphoteric surfactants, the proportion of which is usually about 1 to 70, preferably 5 to 50 and in particular 10 to 30% by weight .
  • anionic surfactants are soaps, alkylbenzenesulfonates, alkanesulfonates, olefin sulfonates, alkyl ether sulfonates, glycerol ether sulfonates, ⁇ -methyl ester sulfonates, sulfo fatty acids, alkyl sulfates, Fatty alcohol ether sulfates, Glycerol ether, Fettklareethersulfate, Hydroxymischethersulfate, monoglyceride (ether) sulfates, fatty acid amide (ether) sulfates, mono- and dialkyl sulfosuccinates, mono- and dialkyl
  • anionic surfactants contain polyglycol ether chains, they can have a conventional, but preferably a narrow, homolog distribution.
  • Typical examples of nonionic surfactants are fatty alcohol polyglycol ethers, alkylphenol polyglycol ethers, fatty acid polyglycol esters, fatty acid amide polyglycol ethers, fatty amine polyglycol ethers, alkoxylated triglycerides, mixed ethers or mixed formals, optionally partially oxidized alk (en) yl oligoglycosides or especially glucoramide acid vegetable derivatives, fatty acid glucoronic acid protein derivatives, fatty acid glucoronic acid protein derivatives Wheat base), polyol fatty acid esters, sugar esters, sorbitan esters, polysorbates and amine oxides.
  • nonionic surfactants contain polyglycol ether chains, they can have a conventional, but preferably a narrow, homolog distribution.
  • cationic surfactants are quaternary ammonium compounds, such as, for example, dimethyldistearylammonium chloride, and esterquats, in particular quaternized fatty acid trialkanolamine ester salts.
  • amphoteric or zwitterionic surfactants are alkyl betaines, alkyl amidobetaines, aminopropionates, aminoglycinates, imidazolinium betaines and sulfobetaines. The surfactants mentioned are exclusively known compounds.
  • Typical examples of particularly suitable mild, ie particularly skin-compatible, surfactants are Fettalkoholpolyglycol- ether sulfates, monoglyceride sulfates, mono- and / or dialkyl sulfosuccinates, fatty acid isethionates, fatty acid sarcosinates, fatty acid taurides, fatty acid glutamates, ⁇ -olefin sulfonates, ethercarboxylic acids, alkyl oligoglucosides, fatty acid glucamides, alkylamidobetaines, amphoacetals and / or protein fatty acid condensates , the latter preferably based on wheat proteins.
  • esters of linear C6-C22 fatty acids with branched alcohols in particular 2-ethylhexanol
  • esters of Ci8-C38 alkylhydroxycarboxylic acids with linear or branched C6-C22- Fatty alcohols especially dioctyl malates, esters of linear and / or branched fatty acids with polyhydric alcohols (such as propylene glycol, dimer diol or trimer triol) and / or Guerbet alcohols, triglycerides based on C6-C ⁇ o fatty acids, liquid mono- / di-triglyceride mixtures based on C ⁇ -Ci ⁇ fatty acids, esters of C ⁇ -C ⁇ fatty alcohols and / or Guerbet alcohols with aromatic carboxylic acids, especially benzoic acid, esters of C2-Ci2-dicarboxylic acids with linear or branched alcohols with 1 to 22 carbon atoms or polyols with 2 to 10 carbon atoms and
  • Suitable emulsifiers are nonionic surfactants from at least one of the following groups:
  • Partial esters of polyglycerol (average degree of self-condensation 2 to 8), polyethylene glycol (molecular weight 400 to 5000), trimethylolpropane, pentaerythritol, sugar alcohols (e.g. sorbitol), alkyl glucosides (e.g. methyl glucoside, butyl glucoside, lauryl glucoside) and polyglucosides (e.g. cellulose) / or unsaturated, linear or branched fatty acids with 12 to 22 carbon atoms and / or hydroxycarboxylic acids with 3 to 18 carbon atoms and their adducts with 1 to 30 moles of ethylene oxide;
  • Polymer emulsifiers e.g. Pemulen types (TR-1, TR-2) from Goodrich; Polyalkylene glycols as well
  • adducts of ethylene oxide and / or of propylene oxide with fatty alcohols, fatty acids, alkylphenols or with castor oil are known, commercially available products. These are mixtures of homologs whose average degree of alkoxylation is the ratio of the amounts of ethylene oxide and / or propylene oxide and substrate, with which the addition reaction is carried out.
  • Ci2 / i8 fatty acid monoesters and diesters of adducts of ethylene oxide with glycerol are known as refatting agents for cosmetic preparations.
  • Alkyl and / or alkenyl oligoglycosides their preparation and their use are known from the prior art. They are produced in particular by reacting glucose or oligosaccharides with primary alcohols with 8 to 18 carbon atoms.
  • the glycoside residue both monoglycosides in which a cyclic sugar residue is glycosidically bonded to the fatty alcohol and oligomeric glycosides with a degree of oligomerization of up to preferably about 8 are suitable.
  • the degree of oligomerization is a statistical mean value which is based on a homolog distribution customary for such technical products.
  • Suitable partial glycerides are hydroxystearic acid monoglyceride, stearic acid diglyceride hydroxy, isostearic acid, Isostearinklarediglycerid, oleic acid monoglyceride, oleic acid diglyceride, Ricinolklaremoglycerid, Ricinolklarediglycerid, Linolklaremonoglycerid, linoleic acid diglyceride, LinolenTalkremonoglycerid, Linolenchurediglycerid, Erucaklaklamonoglycerid, erucic acid diglyceride, Weinchuremonoglycerid, Weinchu rediglycerid, Citronenklamonoglycerid, Citronendiglyce- rid , Malic acid monoglyceride, malic acid diglyceride and their technical mixtures, which may still contain small amounts of triglyceride from the manufacturing process. Addition products of 1 to 30, preferably
  • polyglycerol esters are polyglyceryl-2 dipolyhydroxystearate (Dehymuls® PGPH), polyglycerol-3-diisostearate (Lameform® TGI), polyglyceryl-4 isostearate (Isolan® Eq 34), Polyglyceryl-3 Oleate, Diisostearoyl Polyglyceryl-3 Diisostearate (Isolan® PDI), Polyglyceryl-3 Methylglucose Distearate (Tego Care® 450), Polyglyceryl-3 Beeswax (Cera Bellina®), Polyglyceryl-4 Caprate (Polyglycerol Caprate T2010 / 90), Polyglyceryl-3 Cetyl Ether (Chimexane® NL), Polyglyceryl-3 Distearate (Cremophor® GS 32) and Polyglyceryl Polyricinoleate (Admul® WOL 1403) Polyglyceryl Dimerate Is
  • polystyrene resin examples include the mono-, di- and triesters of trimethylolpropane or pentaerythritol with lauric acid, coconut fatty acid, taig fatty acid, palmitic acid, stearic acid, oleic acid, behenic acid and the like which are optionally reacted with 1 to 30 mol of ethylene oxide.
  • Zwitterionic surfactants can also be used as emulsifiers.
  • Zwitterionic surfactants are surface-active compounds that contain at least one quaternary ammonium group and at least one carboxylate and one sulfonate group in the molecule.
  • Particularly suitable zwitterionic surfactants are the so-called betaines such as the N-alkyl-N, N-dimethylammonium glycinate, for example the coconut alkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinate, for example the coconut acylaminopropyldimethylammonium glycinate, and 2-alkyl-3-carboxylm -hydroxyethylimidazolines each having 8 to 18 carbon atoms in the alkyl or acyl group and the cocoacylaminoethylhydroxyethylcarboxymethylglycinate.
  • betaines such as the N-alkyl-N, N-dimethylammonium glycinate, for example the coconut alkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinate
  • Suitable emulsifiers are ampholytic surfactants.
  • Ampholytic surfactants are surface-active compounds which, in addition to a Cs ⁇ -alkyl or -acyl group, contain at least one free amino group and at least one -COOH or -SOßH group in the molecule and are capable of forming internal salts.
  • ampholytic surfactants are N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each with about 8 to 18 carbon atoms in the alkyl group.
  • Particularly preferred ampholytic surfactants are N-cocoalkylaminopropionate, cocoacylaminoethylaminopropionate and Ci2 / i8-acylsarcosine.
  • cationic surfactants are also suitable as emulsifiers, those of the esterquat type, preferably methylquaternized difatty acid triethanolamine ester salts, being particularly preferred.
  • Typical examples of fats are glycerides, ie solid or liquid vegetable or animal products which essentially consist of mixed glycerol esters of higher fatty acids.
  • Natural waxes such as candelilla wax, carnauba wax, Japanese wax, esparto grass wax, cork wax, guaruma wax, rice germ oil wax, sugar cane wax, come among others , Ouricury wax, montan wax, beeswax, shellac wax, walrus, lanolin (wool wax), pretzel fat, ceresin, ozokerite (earth wax), petrolatum, paraffin waxes, micro waxes; chemically modified waxes (hard waxes), such as montan ester waxes, Sasol waxes, hydrogenated jojoba waxes and synthetic waxes, such as polyalkylene waxes and polyethylene glycol waxes.
  • Fat-like substances such as lecithins and phospholipids are also suitable as additives.
  • lecithins are also often referred to in the professional world as phosphatidylcholines (PC).
  • PC phosphatidylcholines
  • Examples of natural lecithins are the cephalins, which are also referred to as phosphatidic acids and are derivatives of 1,2-diacyl-sn-glycerol-3-phosphoric acids.
  • phospholipids are usually understood to be mono- and preferably diesters of phosphoric acid with glycerol (glycerol phosphates), which are generally classed as fats.
  • glycerol phosphates glycerol phosphates
  • sphingosines or sphingolipids are also suitable.
  • Pearlescent waxes are: alkylene glycol esters, especially ethylene glycol distearate; Fatty acid alkanolamides, especially coconut fatty acid diethanolamide; Partial glycerides, especially stearic acid monoglyceride; Esters of polyvalent, optionally hydroxy-substituted carboxylic acids with fatty alcohols having 6 to 22 carbon atoms, especially long-chain esters of tartaric acid; Fatty substances, such as, for example, fatty alcohols, fatty ketones, fatty aldehydes, fatty ethers and fatty carbonates, which have a total of at least 24 carbon atoms, especially lauron and distearyl ether; Fatty acids such as stearic acid, hydroxystearic acid or behenic acid, ring opening products of olefin epoxides with 12 to 22 carbon atoms with fatty alcohols with 12 to 22 carbon atoms and / or polyols with 2 to 15 carbon atoms
  • Suitable consistency agents are primarily fatty alcohols or hydroxyfatty alcohols with 12 to 22 and preferably 16 to 18 carbon atoms and also partial glycerides, fatty acids or hydroxyfatty acids. A combination of these substances with alkyl oligoglucosides and / or fatty acid N-methylglucamides of the same chain length and / or polyglycerol poly-12-hydroxystearates is preferred.
  • Suitable thickeners are, for example, Aerosil types (hydrophilic silicas), polysaccharides, in particular xanthan gum, guar guar, agar agar, alginates and tyloses, carboxymethyl cellulose and hydroxyethyl cellulose, as well as higher molecular weight polyethylene glycol mono- and diesters of fatty acids , Polyacrylates, (e.g.
  • surfactants such as, for example ethoxylated fatty acid glycerides, esters of fatty acids with polyols such as pentaerythritol or trimethylolpropane, fatty alcohol ethoxylates with a narrow homolog distribution or alkyl oligoglucosides as well as
  • Substances such as, for example, lanolin and lecithin and polyethoxylated or acylated lanolin and lecithin derivatives, polyol fatty acid esters, monoglycerides and fatty acid alkanolamides can be used as superfatting agents, the latter simultaneously serving as foam stabilizers.
  • Suitable cationic polymers are, for example, cationic cellulose derivatives, such as, for example, a quaternized hydroxyethyl cellulose, which is available under the name Polymer JR 400® from Amerchol, cationic starch, copolymers of diallylammonium salts and acrylamides, quaternized vinylpyrrolidone / vinylimidazole polymers, such as, for example, Luviquat® (BASF) , Condensation products of polyglycols and amines, quaternized collagen polypeptides, such as, for example, lauryldimonium hydroxypropyl hydrolyzed collagen (Lamequat®L / Grünau), quaternized wheat polypeptides, polyethyleneimine, cationic silicone polymers, such as, for example, amodimethicones,
  • Suitable anionic, zwitterionic, amphoteric and nonionic polymers are, for example, vinyl acetate / crotonic acid copolymers, vinylpyrrolidone / vinyl acrylate copolymers, vinyl acetate / butyl maleate / isobornyl acrylate copolymers, methyl vinyl ether / maleic anhydride copolymers and esters thereof, uncrosslinked and polyol-crosslinked polyacrylic acids, acrylamidopropyl trimethylammonium chloride / acrylate Copolymers, octylacrylamide / methyl methacrylate / tert-butylaminoethyl methacrylate / 2-hydroxyproyl methacrylate copolymers, polyvinyl pyrrolidone, vinyl pyrrolidone / vinyl acetate copolymers, vinyl pyrrolidone / dimethylaminoethyl methacrylate / vinyl caprolact
  • Suitable silicone compounds are, for example, dimethylpolysiloxanes, methylphenylpolysiloxanes, cyclic silicones and amino-, fatty acid-, alcohol-, polyether-, epoxy-, fluorine-, glycoside- and / or alkyl-modified silicone compounds, which can be both liquid and resinous at room temperature.
  • Simethicones which are mixtures of dimethicones with an average chain length of 200 to 300 dimethylsiloxane units and hydrogenated silicates, are also suitable.
  • Biogenic active substances are, for example, tocopherol, tocopherol acetate, tocopherol palmitate, ascorbic acid, deoxyribonucleic acid, retinol, bisabolol, allantoin, phytantriol, panthenol, AHA acids, amino acids, ceramides, pseudoceramides, essential oils, other plant extracts and vitamine complexes.
  • Body odors arise from the action of skin bacteria on apocrine sweat, whereby unpleasant smelling breakdown products are formed. Accordingly included Deodorants Active ingredients that act as germ inhibitors, enzyme inhibitors, odor absorbers or odor suppressors.
  • germ-inhibiting agents such as.
  • Esterase inhibitors are suitable as enzyme inhibitors. These are preferably trialkyl citrates such as trimethyl citrate, tripropyl citrate, triisopropyl citrate, tributyl citrate and in particular triethyl citrate (Hydagen® CAT).
  • the substances inhibit enzyme activity and thereby reduce odor.
  • esterase inhibitors include sterol sulfates or phosphates, such as, for example, lanosterol, cholesterol, campesteric, stigmasterol and sitosterol sulfate or phosphate, dicarboxylic acids and their esters, such as, for example, glutaric acid, glutaric acid monoethyl ester, glutaric acid diethyl ester, adipic acid, Monoethyl adipate, diethyl adipate, malonic and diethyl malonate, hydroxycarboxylic acids and their esters such as citric acid, malic acid, tartaric acid or tartaric acid diethyl ester, and zinc glycinate.
  • sterol sulfates or phosphates such as, for example, lanosterol, cholesterol, campesteric, stigmasterol and sitosterol sulfate or phosphate
  • dicarboxylic acids and their esters such as, for example, glutaric acid,
  • Suitable odor absorbers are substances that absorb odor-forming compounds and can retain them to a large extent. They lower the partial pressure of the individual components and thus also reduce their speed of propagation. It is important that perfumes must remain unaffected. Odor absorbers are not effective against bacteria. They contain, for example, a complex zinc salt of ricinoleic acid or special, largely odorless fragrances, which are known to the person skilled in the art as "fixators", such as, for example, the main component. B. extracts of Labdanum or Styrax or certain abietic acid derivatives. Fragrance agents or perfume oils act as odor maskers and, in addition to their function as odor maskers, give the deodorants their respective fragrance.
  • Perfume oils are, for example, mixtures of natural and synthetic fragrances. Natural fragrances are extracts of flowers, stems and leaves, fruits, fruit peels, roots, woods, herbs and grasses, needles and branches as well as resins and balms. Animal raw materials, such as civet and castoreum, are also suitable. Typical synthetic fragrance compounds are products of the ester, ether, aldehyde, ketone, alcohol and hydrocarbon type.
  • Fragrance compounds of the ester type are, for example, benzyl acetate, p-tert-butylcyclohexyl acetate, linalyl acetate, phenylethyl acetate, linalyl benzoate, benzyl formate, allyl cyclohexyl propionate, styrallyl propionate and benzyl salicylate.
  • the ethers include, for example Benzyl ethyl ether, for the aldehydes, for example, the linear alkanals with 8 to 18 carbon atoms, citral, citronellal, citronelly loxy acetaldehy, cyclamenaldehyde, hydroxycitronellal, lilial and bourgeonal, for the ketones, for example the jonones and methylcedryl ketone, for the alcohols anethole, citronelloeolene, eugenol , Geraniol, linalool, phenylethyl alcohol and terpineol, the hydrocarbons mainly include the terpenes and balsams.
  • fragrance oils of lower volatility which are mostly used as aroma components, are also suitable as perfume oils, e.g. sage oil, chamomile oil, clove oil, lemon balm oil, mint oil, cinnamon leaf oil, linden blossom oil, juniper berry oil, vetiver oil, oliban oil, galbanum oil, labdanum oil and lavandin oil.
  • Antiperspirants reduce sweat formation by influencing the activity of the eccrine sweat glands and thus counteract armpit wetness and body odor.
  • Aqueous or anhydrous formulations of antiperspirants typically contain the following ingredients:
  • non-aqueous solvents such as As ethanol, propylene glycol and / or glycerin.
  • Salts of aluminum, zirconium or zinc are particularly suitable as astringent antiperspirant active ingredients.
  • suitable antiperspirant active ingredients are e.g. Aluminum chloride, aluminum chlorohydrate, aluminum dichlorohydrate, aluminum sesquichlorohydrate and their complex compounds e.g. B. with propylene glycol-1, 2nd Aluminum hydroxyallantoinate, aluminum chloride tartrate, aluminum zirconium trichlorohydrate, aluminum zirconium tetrachlorohydrate, aluminum zirconium pentachlorohydrate and their complex compounds, for. B. with amino acids such as glycine.
  • conventional oil-soluble and water-soluble auxiliaries can be present in smaller amounts in antiperspirants.
  • Such oil soluble aids can e.g. his:
  • Oil-soluble perfume oils are, for example, preservatives, water-soluble fragrances, pH adjusters, for example buffer mixtures, water-soluble thickeners, for example water-soluble natural or synthetic polymers such as, for example, xanthan gum, hydroxyethyl cellulose, polyvinylpyrrolidone or high molecular weight polyethylene oxides.
  • Common film formers are, for example, chitosan, microcrystalline chitosan, quaternized chitosan, polyvinylpyrrolidone, vinylpyrrolidone-vinyl acetate copolymers, polymers of the acrylic acid series, quaternary cellulose derivatives, collagen, hyaluronic acid or its salts and similar compounds.
  • Piroctone olamine (1-hydroxy-4-methyl-6- (2,4,4-trimythylpentyl) -2- (IH) -pyridinone monoethanolamine salt), Baypival® (Climbazole), Ketoconazol®, (4-acetyl-1 - ⁇ -4- [2- (2.4-dichlorophenyl) r-2- (1 H -imidazol-1-ylmethyl) -1, 3-dioxylan-c-4-ylmethoxyphenyl ⁇ piperazine, selenium disulfide, sulfur colloidal, sulfur polyethylene glycol sorbitan monooleate, sulfur ricinole polyethoxylate , Sulfur tar distillates, salicylic acid (or in combination with hexachlorophene), undexylene acid monoethanolamide sulfosuccinate sodium salt, Lamepon® UD (protein undecylenic acid condensate), zinc pyrithione, aluminum pyrithione and magnesium
  • Montmorillonites, clay minerals, pemules and alkyl-modified carbopol types can serve as swelling agents for aqueous phases.
  • Possible insect repellents are N, N-diethyl-m-toluamide, 1, 2-pentanediol or ethyl butylacetylaminopropionate
  • Dihydroxyacetone is suitable as a self-tanner.
  • Arbutin, kojic acid, coumaric acid and ascorbic acid (vitamin C) can be used as tyrosinase inhibitors, which prevent the formation of melanin and are used in depigmenting agents.
  • Hydrotropes such as ethanol, isopropyl alcohol, or polyols can also be used to improve the flow behavior.
  • Polyols that come into consideration here preferably have 2 to 15 carbon atoms and at least two hydroxyl groups.
  • the polyols can also contain further functional groups, in particular amino groups, or be modified with nitrogen. Typical examples are
  • Alkylene glycols such as, for example, ethylene glycol, diethylene glycol, propylene glycol, butylene glycol, hexylene glycol and polyethylene glycols with an average molecular weight of 100 to 1,000 daltons;
  • Methyl compounds such as in particular trimethylolethane, trimethylolpropane, trimethylolbutane, pentaerythritol and dipentaerythritol; > Lower alkyl glucosides, especially those with 1 to 8 carbons in the alkyl radical, such as methyl and butyl glucoside;
  • Dialcohol amines such as diethanolamine or 2-amino-1, 3-propanediol.
  • Suitable preservatives are, for example, phenoxyethanol, formaldehyde solution, parabens, pentanediol or sorbic acid and the other classes of substances listed in Appendix 6, Parts A and B of the Cosmetics Ordinance.
  • Perfume oils include mixtures of natural and synthetic fragrances. Natural fragrances are extracts of flowers (lily, lavender, roses, jasmine, neroli, ylang-ylang), stems and leaves (geranium, patchouli, petitgrain), fruits (anise, coriander, caraway, juniper), fruit peel (bergamot, lemon, Oranges), roots (mace, angelica, celery, cardamom, costus, iris, calmus), wood (pine, sandal, guaiac, cedar, rosewood), herbs and grasses (tarragon, lemongrass, sage, thyme), Needles and twigs (spruce, fir, pine, mountain pine), resins and balms (galbanum, elemi, benzoin, myrrh, olibanum, opoponax).
  • Typical synthetic fragrance compounds are products of the ester, ether, aldehyde, ketone, alcohol and hydrocarbon type. Fragrance compounds of the ester type are, for example, benzyl acetate, phenoxyethyl isobutyrate, p-tert-butylcyclohexyl acetate, linalyl acetate, dimethylbenzylcarbinylacetate, phenylethyl acetate, linalyl benzoate, benzyl formate, ethyl methylphenyl glycinate, allyl cyclohexyl benzylatepylpropionate, and
  • the ethers include, for example, benzyl ethyl ether
  • the aldehydes include, for example, the linear alkanals having 8 to 18 carbon atoms, citral, citronellal, citronellyloxyacetaldehyde,
  • fragrance oils of lower volatility which are mostly used as aroma components, are also suitable as perfume oils, for example sage oil, chamomile oil, clove oil, lemon balm oil, mint oil, cinnamon leaf oil, linden blossom oil, juniper berry oil, vetiver oil, oliban oil, galbanum oil, labolanum oil and lavandin oil.
  • bergamot oil dihydromyrcenol, lilial, lyral, citronellol, phenylethyl alcohol, ⁇ -hexylcinnamaldehyde, geraniol, benzyl acetone, cyclamen aldehyde, linalool, Boisambrene Forte, Ambroxan, indole, hedione, Sandelice, lemon oil, Mandarinenol, orange oil, allyl amyl glycolate, Cyclovertal, lavandin oil, muscatel Sage oil, ß-damascone, geranium oil bourbon, cyclohexyl salicylate, Vertofix Coeur, Iso-E-Super, Fixolide NP, evernyl, iraldein gamma, phenylacetic acid, geranyl acetate, benzyl acetate, rose oxide, romilllate, irot
  • Example 1 100 g of shredded leaves of Cajanus cajan plants from India were transferred to a glass reactor and poured with 2 liters of distilled water. The infusion was heated between 80 and 90 ° C. and extracted with stirring over a period of 1 hour at this temperature. The mixture was then cooled to 20 ° C. and centrifuged for 15 minutes at a speed of 5000 g. The supernatant colloidal liquid was separated from the residue by filtration using a depth filter with an average porosity of 0.450 ⁇ m (from Seitz, Bordeaux France).
  • Mannitol was added as an adjuvant (1 part mannitol to 3 parts filtered supernatant) and the extract was spray dried at an inlet temperature of 185 ° C and an outlet temperature of 80 ° C.
  • the yield of dry product was 17% by weight, based on the dry weight of plants used.
  • Example 2 Example 1 was repeated, but the extraction was carried out with 300 g of crushed leaves of the plant Cajanus cajan from India in 3 80% by weight aqueous methanol. The extraction was carried out with stirring for 1 h at boiling temperature under reflux and the extract was further processed as described. The filtration was carried out as described in Example 1. The alcohol was then first removed at 30 ° C. under reduced pressure and then the aqueous residue was spray-dried as described. The extraction was performed on two samples or batches (Batch A and Batch B) of starting material. The yield of dry product was 12.4% by weight for batch A and 10.9% by weight for batch B, based on the dry weight of the plants used.
  • Example 3 Example 1 was repeated, but the extraction was carried out using 1.9 9 60% by volume aqueous ethanol. The extraction was carried out with stirring for 1 h at a temperature between 50 and 65 ° C and the extract processed as described. The filtration was carried out as described in Example 1. Then the alcohol was first removed at 45 ° C. under reduced pressure and then the residue was dried as described in Example 1. The yield of dry product was 12.5% by weight, based on the dry weight of plants used.
  • a radical-catching substance reacts with the resulting hydroxyl radicals and reduces the formation of pink-colored substances in this reaction mixture.
  • the same reaction was also carried out without EDTA in order to investigate complex-forming properties of the extract with Fe 2+ ions.
  • the results of the last two tests are summarized in Table 2.
  • the radical-trapping properties of extracts from Cajanus cajan were examined in a test with xanthine oxidase as the test system.
  • the enzyme causes the conversion of purine bases, e.g. Adenine or guanine in uric acid, whereby the intermediately formed superoxide forms oxygen radicals, which spontaneously break down into H2O2 and oxygen due to superoxide dismutase (SOD).
  • SOD superoxide dismutase
  • These superoxide radicals can be detected and quantified by reaction with luminol, or luminol and microperoxidase and by NBT via the luminescence and the optical density at 490 nm.
  • the luminescence yield is reduced in the presence of substances with radical-trapping properties.
  • the aim of these tests is to determine the toxic concentration of the agent under investigation for fibroblasts in order to better determine the most effective concentration.
  • the still effective concentration range can thus be limited.
  • DMEM Dulbecco Minimum Essential Medium, company Life Technologie Sari
  • Calf serum inoculated and incubated for 24 h at 37 ° C in a 5% CO ⁇ atmosphere.
  • the nutrient medium with fetal calf serum was then replaced by a nutrient medium from DMEM without fetal calf serum.
  • Different concentrations of plant extract were added to this nutrient medium.
  • the growth and metabolic activity were assessed by measuring the intracellular proportion of ATP according to the enzymatic luminescence method of Vasseur (Journal francais Hydrologie, 1981, 9, 149-156.) And the proportion of cell proteins was determined by the method of Bradford (Anal. Biochem., 1976, 72,, 248-254).
  • the determination of the proportion of cellular proteins allows a conclusion to be drawn about the proportion of macromolecules such as enzymes, collagen, elastin or other dermal macromolecules which are necessary for the formation of connective tissue.
  • macromolecules such as enzymes, collagen, elastin or other dermal macromolecules which are necessary for the formation of connective tissue.
  • the ATP content of a cell is important for many enzymes, the activity of which depends on this energy carrier.
  • the lethal dose of the extract from Cajanus cajan was determined at which 50% of the fibroblasts examined were no longer viable (LD 50). Up to a concentration of 0.005% by weight, the extract from Cajanus cajan shows no toxic effects on human fibroblasts.
  • Example 6 Cell protection action against UVA on human fibroblasts grown in vitro
  • UVA rays penetrate into the dermis, where they lead to oxidation stress, which is demonstrated by lipoperoxidation of the cytoplasmic membranes.
  • the lipoperoxides are broken down to malonaldehyde, which will crosslink many biological molecules such as proteins and nucleic bases (enzyme inhibition or mutagenesis).
  • DMEM defined culture medium
  • the culture medium was replaced by saline solution (physiological NaCI solution) and the fibroblasts were irradiated with a UVA dose (365 nm, 3-15 J / cm 2 ; tubes: MAZDA FLUOR TFWN40).
  • the MDA level (malonaldialdehyde level) in the supernatant sodium chloride solution was determined quantitatively by reaction with thiobarbituric acid.
  • the protein content was determined by the Bradford method.
  • Example 7 Cell protection action against UVB on human keratinocytes grown in vitro
  • UVB rays trigger inflammation (erythema, edema) by activating an enzyme, namely phospholipase A2 or PLA2, which removes arachidonic acid from the phospholipids of the plasma membrane.
  • DMEM defined medium
  • fetal calf serum was inoculated with the keratinocytes and the plant extract (diluted with saline solution) was added 72 hours after the inoculation.
  • the keratinocytes were then irradiated with a UVB dose (50 mJ / cm 2 - tubes: DUKE FL40E).
  • LDH- lactate dehydrogenase
  • PGE2 ELISA test
  • the macrophages and polymorphonuclear neutrophil granulocytes proteases such as e.g. the serine protease elastase or matrix metalloproteases (MMP) such as collagenase and another elastin degrading elastase belonging to the MMP are released.
  • MMP matrix metalloproteases
  • proteases catalyze the fragmentation and destruction of the dermal macromolecules such as proteoglycan, collagen and elastin and thus lead to the aging of the skin and to the effects of natural skin aging after UV radiation.
  • Serine proteases e.g. a type of elastase, break down elastin, proteoglycans and collagen and thus weaken the connective tissue.
  • the inhibitory properties of the extract according to Example 2 were investigated on a chromogenic synthetic substrate (obtained from SIGMA). The incubation time was 30 min at room temperature. The inhibition was monitored photometrically at 410 nm, using ⁇ 1-antitrypsin as the positive standard. The results are summarized in Table 6.
  • the extract thus shows an activity against the serine protease elastase. This activity leads to the possible use against effects of skin aging, which are due to an increased activity of the serine protease elastase.
  • MMP-1 matrix metallo-protease-1
  • a first test collagenase from Clostridium histolyticum was examined, which was labeled with chromogenic synthetic substrate FALGPA was. The incubation time was 30 min at room temperature. The hydrolysis of collagen was determined photometrically at 324 nm. Cysteine or EDTA was used as the reference substance.
  • type I collagen was treated with glucose and the extracts at 45 ° C. for 21 days. The suspensions were then centrifuged and the content of Schiff's bases in the supernatant liquid was determined by fluorescence measurement at 430 nm. The results are summarized in Table 7. The data refer to the control as standards (without extract and without glucose).
  • the results demonstrate a reducing activity on the non-enzymatic glycosylation of collagen and thus a reducing effect on the aging of the dermis.
  • the evaluation of the modification of sensory properties on human hair after treatment with extracts of the Cajanus cajan plant was carried out on standardized strands of hair (20 cm in length and 5 g in weight).
  • the samples of the plant extracts were incorporated into a shampoo at a concentration of 1.5% by weight and tested.
  • the combability was tested on the dried hair before and after the treatment with the shampoo.
  • the hair tresses were washed with aqueous sodium lauryl sulfate solution (15% by weight).
  • the hair strands were fixed at the upper end and the force that has to be applied for combing was measured in a standardized device, under air-conditioned conditions, by guiding the comb through the strand at a constant speed.
  • the hair strands were treated with 3 ml of shampoo containing the extract from Cajanus cajan for 3 minutes. The strand of hair was then 1 min. rinsed with water. The strand of hair treated in this way was likewise stored overnight at 22 ° C. and 40% atmospheric humidity in the air-conditioned housing and tested three times with the same combability tests.
  • the highest force was determined, which had to be applied during the combing process and, on the other hand, the total combing work, which is expressed by the mean value of the measured force in the respective combability tests.
  • the extracts of Cajanus cajan are suitable for the care of hair because they improve the combability of dry hair.
  • Example 10 Example formulations of cosmetic agents with extracts of the plants Cajanus cajan
  • the extracts of the plant Cajanus cajan obtained according to Examples 1 to 3 were used in the following formulations K1 to K21 and 1 to 40 according to the invention. Unless explicitly stated otherwise, each extract according to Examples 1 to 3 can be used.
  • the cosmetic compositions produced in this way showed very good skin-care properties and, at the same time, good skin tolerance compared to the comparison formulations V1, V2 and V3.
  • the agents according to the invention prove to be stable against oxidative decomposition.
  • Glycerin (86% by weight) 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0
  • Extracts from Cajanus cajan (Example 1-3) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
  • Glycerin (86% by weight) 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0
  • Glycerin (86% by weight) 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0
  • Cosmetic preparations conditioner (water, preservative ad 100 wt.%)
  • Cosmetic preparations conditioner (water, preservative ad 100 wt .-%)
  • Table 13 Cosmetic preparations shampoo (water, preservative ad 100 wt .-%)
  • Table 13 Cosmetic preparations bubble bath (water, preservative ad 100 wt .-%)

Abstract

L'invention concerne des préparations cosmétiques et/ou pharmaceutiques contenant un extrait végétal de la plante Cajanus cajan. L'invention concerne également l'utilisation universelle d'extraits végétaux de Cajanus cajan dans des produits de soin pour la peau et/ou les cheveux, par exemple, dans des produits de protection solaire, notamment comme agents anti-inflammatoires, anti-oxydants ou capteurs de radicaux libres, agents contre le vieillissement cutané, inhibiteurs de protéase, agents d'anti-glycosylation et agents de soin capillaire antidémêlant. L'invention concerne également un procédé de production d'un extrait de Cajanus cajan.
EP02764769A 2001-08-02 2002-07-24 Preparations cosmetiques et/ou pharmaceutiques contenant des extraits vegetaux Withdrawn EP1411890A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02764769A EP1411890A1 (fr) 2001-08-02 2002-07-24 Preparations cosmetiques et/ou pharmaceutiques contenant des extraits vegetaux

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01402096 2001-08-02
EP01402096A EP1281392A1 (fr) 2001-08-02 2001-08-02 Compositions cosmétiques et/ou pharmaceutiques contenant des extraits de plantes
EP02764769A EP1411890A1 (fr) 2001-08-02 2002-07-24 Preparations cosmetiques et/ou pharmaceutiques contenant des extraits vegetaux
PCT/EP2002/008229 WO2003013458A1 (fr) 2001-08-02 2002-07-24 Preparations cosmetiques et/ou pharmaceutiques contenant des extraits vegetaux

Publications (1)

Publication Number Publication Date
EP1411890A1 true EP1411890A1 (fr) 2004-04-28

Family

ID=8182839

Family Applications (2)

Application Number Title Priority Date Filing Date
EP01402096A Withdrawn EP1281392A1 (fr) 2001-08-02 2001-08-02 Compositions cosmétiques et/ou pharmaceutiques contenant des extraits de plantes
EP02764769A Withdrawn EP1411890A1 (fr) 2001-08-02 2002-07-24 Preparations cosmetiques et/ou pharmaceutiques contenant des extraits vegetaux

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP01402096A Withdrawn EP1281392A1 (fr) 2001-08-02 2001-08-02 Compositions cosmétiques et/ou pharmaceutiques contenant des extraits de plantes

Country Status (5)

Country Link
US (1) US20040191190A1 (fr)
EP (2) EP1281392A1 (fr)
JP (1) JP2005504755A (fr)
KR (1) KR20040021685A (fr)
WO (1) WO2003013458A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217690B2 (en) 2003-10-07 2007-05-15 Kimberly-Clark Worldwide, Inc. Compositions of sunflower trypsin inhibitors
KR101414377B1 (ko) * 2003-11-07 2014-07-01 바스프 뷰티 케어 솔루션즈 프랑스 에스에이에스 스키산드라 키넨시스의 과일의 추출물 및 그의 약학용 및 화장용 용도
ES2809302T3 (es) 2004-01-22 2021-03-03 Univ Miami Formulaciones de coenzima Q10 para tratar tumores sólidos mediante administración intravenosa
DK2233127T3 (da) 2004-03-17 2020-08-24 Stada Arzneimittel Ag Anvendelse af antioxidanter til fremstilling af en farmaceutisk eller kosmetisk sammensætning for at beskytte huden mod skader som følge af infrarød stråling
JP2006052178A (ja) * 2004-08-13 2006-02-23 Lion Corp 毛髪化粧料及び毛髪補強・強化剤
WO2006107188A1 (fr) * 2005-04-06 2006-10-12 Fujifilm Manufacturing Europe B.V. Films non poreux pour cultiver des cellules
WO2006107207A2 (fr) * 2005-04-06 2006-10-12 Fujifilm Manufacturing Europe B.V. Pellicule non-poreuse destinee a la culture de cellules
KR100848382B1 (ko) * 2006-05-08 2008-07-24 서명숙 미용조성물 및 이용한 퍼머액
US20080175931A1 (en) * 2007-01-19 2008-07-24 Nathalie Schlemer Cosmetic foundation
EP2136787B1 (fr) 2007-03-22 2019-08-21 Berg LLC Formulations topiques ayant une biodisponibilité amplifiée
CN101172948B (zh) * 2007-11-01 2010-09-22 东北林业大学 一种从木豆枝叶提取物中分离纯化木豆素和球松素的方法
AU2009233785B2 (en) 2008-04-11 2015-08-20 Berg Llc Methods and use of inducing apoptosis in cancer cells
IT1391451B1 (it) * 2008-09-24 2011-12-23 Canalini Preparato per il trattamento della disfunzione erettile
CN102325535A (zh) * 2009-02-23 2012-01-18 帝斯曼知识产权资产管理有限公司 用于炎性病症的cajanus提取物和葡糖胺
WO2010106545A1 (fr) * 2009-03-16 2010-09-23 Cavinkare Pvt. Ltd. Agent de soin cutané et ses compositions
KR20180056816A (ko) 2009-05-11 2018-05-29 베르그 엘엘씨 환경대사적 전환인자（조효소 ｑ１０）를 사용한 질환의 치료 방법
JP5411591B2 (ja) * 2009-06-12 2014-02-12 ホーユー株式会社 毛髪処理剤組成物
EA019746B1 (ru) 2009-09-24 2014-05-30 Юнилевер Нв Противомикробная композиция, содержащая эвгенол, терпинеол и тимол, и способ дезинфицирования поверхности
US8535739B2 (en) * 2010-01-28 2013-09-17 George Lowe Sparkle essence system
AU2011224207B2 (en) 2010-03-12 2015-11-19 Berg Llc Intravenous formulations of Coenzyme Q10 (CoQ10) and methods of use thereof
BR112013013085B1 (pt) 2010-12-07 2018-02-14 Unilever N.V. Composição de cuidados orais, enxaguante bucal, creme dental, dentífrico, método para desinfetar a cavidade oral e uso de uma composição
US20120269867A1 (en) 2011-04-04 2012-10-25 Jimenez Joaquin J Methods of treating central nervous system tumors
PE20140628A1 (es) 2011-06-17 2014-05-30 Berg Llc Composiciones farmaceuticas inhalables
WO2013064360A2 (fr) 2011-11-03 2013-05-10 Unilever N.V. Composition pour hygiène personnelle
KR101438517B1 (ko) * 2012-06-13 2014-09-17 경희대학교 산학협력단 플라반-3-올 다합체, 그 유도체 또는 이들의 허용 가능한 염을 유효성분으로 포함하는 여드름 예방, 개선 및 치료용 조성물
SG11201508272YA (en) 2013-04-08 2015-11-27 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
SG10201907816RA (en) 2013-09-04 2019-09-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
KR101887168B1 (ko) * 2016-12-22 2018-08-10 주식회사 인투바이오 열에 의한 피부 노화 예방용 조성물
KR101887140B1 (ko) * 2016-12-22 2018-08-09 주식회사 인투바이오 열에 의한 피부 노화 예방용 조성물
KR101899345B1 (ko) * 2017-02-10 2018-09-17 대봉엘에스 주식회사 TES Trioleate를 포함하는 자외선에 대한 피부 보호용 조성물
US20200282001A1 (en) * 2017-10-13 2020-09-10 Better And Beautiful Humanity Research, Llc Lemon Grass Powder Extraction for Digestive Problems, Irritable Bowel Syndrome with Diarrhea, Abdominal Cramps, Abdominal Bloating, Travelers Diarrhea, Small Intestinal Bacterial Overgrowth, and Bloating
CN111281812A (zh) * 2018-12-10 2020-06-16 深圳市前海博斐生物科技有限公司 木豆素的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172887A (en) * 1973-11-30 1979-10-30 L'oreal Hair conditioning compositions containing crosslinked polyaminopolyamides
US4677065A (en) * 1986-03-24 1987-06-30 Aktieselskabet De Danske Sukkerfabrikker Production of improved protein isolate derived from seeds of a grain legume
EP0532465B1 (fr) * 1991-09-13 2002-07-10 Pentapharm A.G. Fraction protéinique pour les soins cosmétiques et dermatologiques de la peau
JPH0710768A (ja) * 1993-05-24 1995-01-13 Suntory Ltd マメ科植物抽出物を有効成分とするヒアルロニダーゼ阻害剤
DE4426215A1 (de) * 1994-07-23 1996-01-25 Merck Patent Gmbh Ketotricyclo [5.2.1.0] decan-Derivate
DE4426216A1 (de) * 1994-07-23 1996-01-25 Merck Patent Gmbh Benzyliden-Norcampher-Derivate
DE59709127D1 (de) * 1996-07-08 2003-02-20 Ciba Sc Holding Ag Triazinderivate als UV-Filter in Sonnenschutzmitteln
DE59712388D1 (de) * 1996-11-29 2005-09-15 Basf Ag Photostabile UV-A-Filter enthaltende kosmetische Zubereitungen
US6004558A (en) * 1998-02-25 1999-12-21 Novogen, Inc. Methods for treating cancer with legume plant extracts
DE19911053B4 (de) * 1999-03-12 2004-10-28 Biotec Asa Kosmetische und/oder pharmazeutische Zubereitungen
KR20010102559A (ko) * 1999-03-31 2001-11-15 카스파르 스튀름, 아를레테 슐레퍼 화장품 및 피부과용 피부관리 조성물
WO2000078324A1 (fr) * 1999-06-18 2000-12-28 Hao Yuan Extraits, preparation et applications de medicaments a base de feuilles de cajanus cajan (l.) milsp
AU2001253070A1 (en) * 2000-03-31 2001-10-15 Jonathan Ingram Isoflavones for treatment of obesity
EP1174144A1 (fr) * 2000-07-20 2002-01-23 Linnea S.A. Extrait sec riche en isoflavones et procédé de préparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03013458A1 *

Also Published As

Publication number Publication date
US20040191190A1 (en) 2004-09-30
WO2003013458A1 (fr) 2003-02-20
EP1281392A1 (fr) 2003-02-05
JP2005504755A (ja) 2005-02-17
KR20040021685A (ko) 2004-03-10

Similar Documents

Publication Publication Date Title
EP1347768B1 (fr) Preparations cosmetiques et/ou dermopharmaceutiques contenant des extraits de feuilles de la plante i argania spinosa /i
WO2003013458A1 (fr) Preparations cosmetiques et/ou pharmaceutiques contenant des extraits vegetaux
EP1339421B1 (fr) Preparations cosmetiques ou dermopharmaceutiques contenant des proteines natives de la plante argania spinosa
EP1296701B1 (fr) Utilisation d'extraits du champignon grifola frondosa
EP1239826A2 (fr) Preparations cosmetiques et/ou pharmaceutiques
EP1372685B1 (fr) Utilisation d'extraits de la plante litchi chinensis sonn.
WO2001058412A2 (fr) Extraits de residus de la production de vin
EP1351662A1 (fr) Preparations cosmetiques et/ou pharmaceutiques
WO2001062223A2 (fr) Preparations cosmetiques contenant des extraits vegetaux
EP1313497A1 (fr) Utilisation d'extraits de la plante cassia alata
EP1441747B1 (fr) Utilisation d'un extrait de plante dite vigna aconitfolia dans une composition cosmetique et/ou dermopharmaceutique
WO2001078675A1 (fr) Utilisation de matieres naturelles pour produire des preparations cosmetiques
EP1276460B1 (fr) Utilisation de preparations contenant un extrait de la plante argania spinosa dans des produits de soin cosmetiques pour les cheveux et la peau
WO2002098384A1 (fr) Preparations cosmetiques et/ou pharmaceutiques contenant un extrait de pterocarpus marsupium
WO2003043595A1 (fr) Agents anti-vieillissement
EP1635910A1 (fr) Preparations cosmetiques et/ou dermatologiques contenant un extrait des semences de plantes de l'espece adenanthera
WO2001052809A1 (fr) Preparations cosmetiques ou pharmaceutiques contenant une quantite efficace d'un extrait d'arrabidaea chica
EP1292278B1 (fr) Preparations renfermant un extrait de plantes pistia stratiotes
WO2003053374A1 (fr) Utilisation d'un extrait de la plante baptisia tinctoria dans une composition cosmetique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

17Q First examination report despatched

Effective date: 20050629

REG Reference to a national code

Ref country code: DE

Ref legal event code: 8566

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: COGNIS FRANCE, S.A.S.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051110